AIDS research activities at Case Western Reserve University have been characterized by initial development along areas of existing strengths in international aspects of AIDS and mycobacterial research; the award of an AIDS Clinical Trials Unit (ACTU) in 1987 coordinated with the Special Immunology Unit that provides outstanding and comprehensive care to HIV-1 infected persons; and an institutional commitment of resources to develop a Biosafety Level-3 (BL-3) facility and recruit molecular retrovirologists (Drs. Le Grice and Giam). The current NIAID-supported AIDS and AIDS-related research in the funding base is $4,079,761 direct costs for 13 projects. Overall funding of AIDS researchers at CWRU is $5,630,056 direct costs for 26 projects, which will increase to $6,384,877 for 30 projects after September council. This CFAR application proposes to capitalize on the current state of development of AIDS research at CWRU to 1) promote increased collaboration between basic and clinical researchers through a central administrative structure, development of appropriate forums for sharing and exchange of ideas and pilot funding for interdisciplinary research; 2) to enhance the depth and breath of AIDS research by coordinated development of core activities and recruitment of new investigators. To achieve these goals 27 CFAR investigators from 10 departments will participate in working groups (international Aspects of AIDS; Mycobacterial Research; Molecular Virology; immunology) and three basic science cores (BL-3, Immunology, Molecular Biology) as well as a clinical research core.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036219-05
Application #
2672348
Study Section
Special Emphasis Panel (SRC (70))
Project Start
1994-04-01
Project End
1998-08-31
Budget Start
1998-04-01
Budget End
1998-08-31
Support Year
5
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Webel, Allison R; Perazzo, Joseph; Longenecker, Christopher T et al. (2018) The Influence of Exercise on Cardiovascular Health in Sedentary Adults With Human Immunodeficiency Virus. J Cardiovasc Nurs 33:239-247
Yan, Junpeng; Shun, Ming-Chieh; Hao, Caili et al. (2018) HIV-1 Vpr Reprograms CLR4DCAF1 E3 Ubiquitin Ligase to Antagonize Exonuclease 1-Mediated Restriction of HIV-1 Infection. MBio 9:
Silver, Nicholas; Paynter, Mary; McAllister, Georgina et al. (2018) Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay. AIDS Res Ther 15:18
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150
Martinez, Leonardo; Handel, Andreas; Shen, Ye et al. (2018) A Prospective Validation of a Clinical Algorithm to Detect Tuberculosis in Child Contacts. Am J Respir Crit Care Med 197:1214-1216
Fitzgerald, Wendy; Freeman, Michael L; Lederman, Michael M et al. (2018) A System of Cytokines Encapsulated in ExtraCellular Vesicles. Sci Rep 8:8973
Dazard, Jean-Eudes; Ishwaran, Hemant; Mehlotra, Rajeev et al. (2018) Ensemble survival tree models to reveal pairwise interactions of variables with time-to-events outcomes in low-dimensional setting. Stat Appl Genet Mol Biol 17:
Mukherjee, Pranab K; Chandra, Jyotsna; Retuerto, Mauricio et al. (2018) Dysbiosis in the oral bacterial and fungal microbiome of HIV-infected subjects is associated with clinical and immunologic variables of HIV infection. PLoS One 13:e0200285
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Tomalka, Amanda G; Resto-Garay, Ivelisse; Campbell, Kerry S et al. (2018) In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol 9:2552

Showing the most recent 10 out of 539 publications